NAD+ is the central cellular redox coenzyme and substrate for sirtuins (SIRT1-7) and PARPs — declining ~50% with age, studied extensively in preclinical aging, metabolic, and neurodegenerative research.
Product definition
What is NAD+?
NAD+ is the central cellular redox coenzyme and substrate for sirtuins (SIRT1-7) and PARPs — declining ~50% with age, studied extensively in preclinical aging, metabolic, and neurodegenerative research.
NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme present in all living cells, functioning in two pharmacologically distinct roles: as an electron carrier (redox cycling between NAD+ and NADH) in glycolysis, the TCA cycle, and the mitochondrial electron transport chain; and as a consumed substrate for non-redox enzymes including sirtuins (SIRT1-7, histone deacylases), PARPs (DNA repair), CD38/CD157 (cAMP signaling), and SARM1 (axonal degeneration).
The aging biology significance is the documented decline: NAD+ tissue concentrations fall approximately 50% between young adulthood and age 60 in humans, a decline attributed to increased CD38 NADase activity with age, decreased NAD+ biosynthesis pathway efficiency, and increased PARP consumption during accumulating DNA damage. This decline has been studied as a causal contributor to the hallmarks of aging: mitochondrial dysfunction, increased genomic instability, impaired cellular senescence regulation, and chronic inflammation (sirtuins regulate NF-κB activity). Preclinical NMN and NR studies in mice have demonstrated that restoring NAD+ levels reverses some of these aging-associated endpoints, driving substantial investment in clinical research.
Research context
How is NAD+ described in the research literature?
NAD+ functions as electron carrier in mitochondrial energy metabolism and as consumed co-substrate for sirtuins (deacylation, gene regulation, mitochondrial function) and PARPs (DNA strand break repair via ADP-ribosylation). Age-associated decline in NAD+ reduces both sirtuin and PARP activity; repletion in preclinical models restores these functions and improves metabolic, neurological, and aging endpoints.
Compound profile
Key facts about NAD+
- Class
- Dinucleotide coenzyme / sirtuin & PARP substrate
- Molecular weight
- ~663 Da
- Age-related decline
- ~50% reduction in tissue levels by age 60
- Key enzyme consumers
- Sirtuins (SIRT1-7), PARPs, CD38, SARM1
- CAS
- 53-84-9
- Research category
- Aging biology, sirtuin pharmacology, DNA repair, mitochondrial function
- Storage
- Lyophilized: −20°C, protected from light. Reconstituted: 2–8°C, use within 14 days
Research areas
What research areas is NAD+ associated with?
- Universal substrate for sirtuins (SIRT1-7) — the deacylase family governing mitochondrial biogenesis, DNA repair, and stress response
- PARP1/2 substrate for DNA strand break repair — depleted in aging and after oxidative stress
- Age-associated decline of ~50% by age 60 documented in human tissue studies — the research rationale for NAD+ repletion
- Preclinical NMN/NR studies in rodents document improved metabolic function, muscle physiology, and neurological parameters with NAD+ repletion
- Direct NAD+ bypasses precursor conversion steps — methodologically cleaner for cell culture and ex vivo research systems
- Implicated in all major hallmarks of aging through sirtuin and PARP-dependent mechanisms
Research audience
Who researches NAD+?
NAD+ is used by researchers in aging biology, sirtuin pharmacology, DNA repair, mitochondrial function, metabolic disease, and neurodegeneration. It is the foundational substrate for studying the aging-associated enzyme systems that depend on NAD+ availability and the mechanistic backbone of longevity research.
Preclinical research overview
What does the preclinical literature say about NAD+?
The NAD+ aging hypothesis was formalized by work from David Sinclair's group at Harvard, Johan Auwerx's group at EPFL, and Charles Brenner's group (discoverer of NR), among others. The foundational observation — that NAD+ levels decline with age and that restoring them in mice produces measurable improvements in aging endpoints — was published across multiple high-impact papers between 2013 and 2019, generating substantial academic and commercial interest.
The sirtuin connection is central: SIRT1 deacetylates PGC-1α (mitochondrial biogenesis master regulator), p53 (DNA damage response), NF-κB (inflammation), and FOXO (stress resistance). As NAD+ declines with age, sirtuin activity decreases, potentially contributing to the mitochondrial dysfunction, increased inflammation, and impaired DNA damage response that characterize organismal aging.
PARP competition for NAD+ is a parallel research thread: accumulated DNA damage with age activates PARP1, consuming NAD+ faster than it can be replenished — a potential positive feedback loop where aging causes DNA damage, DNA damage activates PARPs, PARP activation depletes NAD+, and NAD+ depletion further impairs the sirtuin-mediated repair pathways. CD38 inhibition and NAD+ repletion both represent pharmacological approaches to breaking this cycle.
For injectable NAD+ research specifically: direct intravenous or subcutaneous NAD+ administration is used in clinical and translational research contexts to achieve rapid NAD+ repletion without dependence on NMN or NR conversion pathways, whose efficiency varies across tissues and individuals.
Common questions
Frequently asked about NAD+
How does injectable NAD+ compare to oral NMN or NR supplementation?
NMN and NR are NAD+ precursors that must be converted to NAD+ intracellularly via the salvage pathway. Oral bioavailability and tissue-specific conversion efficiency vary. Injectable NAD+ provides direct substrate without conversion dependence, which is methodologically relevant for research requiring precise NAD+ delivery — particularly in cell culture, ex vivo tissue models, or in vivo studies where precursor conversion kinetics would confound interpretation of results. Injectable NAD+ is used where direct NAD+ availability needs to be controlled as an experimental variable.
What is the stability of NAD+ in solution?
NAD+ in solution undergoes hydrolysis at the glycosidic bond, particularly at non-neutral pH and elevated temperature. Lyophilized NAD+ is stable at −20°C for extended periods. Reconstituted solutions should be stored at 2–8°C, used within 14 days, and protected from light (UV exposure accelerates degradation). Use physiological pH buffers for reconstitution to maximize solution stability.
Why is NAD+ relevant to neurodegenerative disease research?
Multiple neurodegeneration mechanisms involve NAD+ depletion: SARM1 (a NAD+ hydrolase) is activated during axonal injury and drives Wallerian degeneration via NAD+ catabolism; PARP overactivation following oxidative DNA damage in neurons is neurotoxic via NAD+ depletion (parthanatos); and sirtuin-mediated neuroprotective pathways (SIRT1 and SIRT3) require adequate NAD+ for activity. NAD+ repletion studies in Alzheimer's, Parkinson's, and TBI rodent models have documented neuroprotective and functional improvement effects.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy